Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyriakos P Papadopoulos

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Expert Opinion on Investigational Drugs|October 10, 2007
Future options for imatinib mesilate-resistant tumorsKamalesh K Sankhala, Kyriakos P Papadopoulos
Expert Opinion on Pharmacotherapy|June 17, 2005
Current chemotherapy options for thymic epithelial neoplasmsKyriakos P Papadopoulos, Charles R Thomas
American Journal of Clinical Oncology|October 7, 2003
Renal medullary carcinoma: case report and review of the literatureWanda G Noguera-Irizarry, Hanina Hibshoosh, Kyriakos P Papadopoulos
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 27, 2007
Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survivalLuci K Leykum, Hashem B El-Serag, John Cornell, et al.
BMC Cancer|August 8, 2018
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trialKyriakos P Papadopoulos, Eytan Ben-Ami, Amita Patnaik, et al.
The Oncologist|November 22, 2017
Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid ChondrosarcomaKyriakos P Papadopoulos, Rebecca S Romero, Gabriela Gonzalez, et al.
British Journal of Clinical Pharmacology|September 3, 2017
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumoursMasaya Tachibana, Kyriakos P Papadopoulos, John H Strickler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid TumorsKyriakos P Papadopoulos, Karen Autio, Talia Golan, et al.
Leukemia & Lymphoma|February 10, 2016
A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphomaKyriakos P Papadopoulos, Javier Lopez-Jimenez, Scott E Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapyFederica Moschella, Brygida Bisikirska, Antonella Maffei, et al.
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Expert Opinion on Investigational Drugs|October 10, 2007
Future options for imatinib mesilate-resistant tumorsKamalesh K Sankhala, Kyriakos P Papadopoulos
Expert Opinion on Pharmacotherapy|June 17, 2005
Current chemotherapy options for thymic epithelial neoplasmsKyriakos P Papadopoulos, Charles R Thomas
American Journal of Clinical Oncology|October 7, 2003
Renal medullary carcinoma: case report and review of the literatureWanda G Noguera-Irizarry, Hanina Hibshoosh, Kyriakos P Papadopoulos
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 27, 2007
Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survivalLuci K Leykum, Hashem B El-Serag, John Cornell, et al.
BMC Cancer|August 8, 2018
Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trialKyriakos P Papadopoulos, Eytan Ben-Ami, Amita Patnaik, et al.
The Oncologist|November 22, 2017
Anti-Hu-Associated Autoimmune Limbic Encephalitis in a Patient with PD-1 Inhibitor-Responsive Myxoid ChondrosarcomaKyriakos P Papadopoulos, Rebecca S Romero, Gabriela Gonzalez, et al.
British Journal of Clinical Pharmacology|September 3, 2017
Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumoursMasaya Tachibana, Kyriakos P Papadopoulos, John H Strickler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid TumorsKyriakos P Papadopoulos, Karen Autio, Talia Golan, et al.
Leukemia & Lymphoma|February 10, 2016
A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphomaKyriakos P Papadopoulos, Javier Lopez-Jimenez, Scott E Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapyFederica Moschella, Brygida Bisikirska, Antonella Maffei, et al.
Pageof 11